tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event

Story Highlights
  • Allogene Therapeutics selected standard FC for its ALPHA3 study after a Grade 5 adverse event linked to ALLO-647.
  • The ALPHA3 trial now compares cema-cel after standard FC to observation, with a futility analysis expected in 2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Allogene Therapeutics ( (ALLO) ) is now available.

On August 1, 2025, Allogene Therapeutics announced the selection of standard fludarabine and cyclophosphamide as the lymphodepletion regimen for its ALPHA3 study, following a Grade 5 adverse event linked to ALLO-647. The decision to close the arm testing FC plus ALLO-647 was made after consultation with the FDA and the DSMB due to severe viral infections attributed to immunosuppression from ALLO-647. The amended ALPHA3 trial will now proceed with two arms, comparing cema-cel after standard FC lymphodepletion to observation, with the next milestone being a futility analysis expected in the first half of 2026. The company will focus on advancing its AlloCAR T product candidates using the Dagger® Platform Technology, which aims to reduce the need for standard lymphodepletion.

The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.

Spark’s Take on ALLO Stock

According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.

The overall stock score reflects significant financial challenges, including declining revenues and persistent losses. While technical analysis and earnings call sentiment provide some hope for future progress, valuation concerns weigh heavily due to negative earnings and the absence of dividends. The company’s ability to navigate operational inefficiencies and improve financial stability will be crucial for future performance.

To see Spark’s full report on ALLO stock, click here.

More about Allogene Therapeutics

Allogene Therapeutics, Inc. operates in the biotechnology industry, focusing on developing allogeneic CAR T cell therapies for cancer treatment. The company is known for its innovative approaches in immuno-oncology, particularly through its AlloCAR T product candidates and proprietary Dagger® Platform Technology.

Average Trading Volume: 3,541,828

Technical Sentiment Signal: Sell

Current Market Cap: $269M

For an in-depth examination of ALLO stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1